Add BrightSurf on Google Email

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: January 23, 2026

This study introduces a new FAP-targeting peptide that shows strong tumor uptake and effective tumor growth inhibition when paired with lutetium-177. Additionally, researchers have identified distinct metabolic and structural brain patterns that differentiate probable LATE, Alzheimer disease, and their frequent overlap.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 23, 2026

Hope for smarter lung cancer care

A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.

SourceFlinders University·JournalCancer Letters·TypeMeta-analysis·DateJan 21, 2026

The Journal of Nuclear Medicine ahead-of-print tip sheet: January 16, 2026

Recent studies published in The Journal of Nuclear Medicine explore the use of interim PET scans to predict treatment response and survival in patients with large B-cell lymphoma. Additionally, a phase 2 trial evaluates the safety and effectiveness of a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) in advanced...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 16, 2026

Novel theranostic model shows curative potential for gastric and pancreatic tumors

A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, completely eradicating tumors in preclinical models. Claudin-18.2-based theranostics could meaningfully change patient care by enabling non-invasive tumor identification and targeted radiation therapy.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 15, 2026

Alliance trial reveals gene variant may affect prostate cancer drug efficacy

A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...

SourceAlliance for Clinical Trials in Oncology·JournalClinical and Translational Science·TypeExperimental study·DateJan 14, 2026

Two wrongs make a right: how two damaging variants can restore health

A study published in PNAS found that over 60% of pairs of damaging genetic variants can restore enzyme activity when combined, challenging long-held assumptions about genetics. This phenomenon, known as intragenic complementation, has implications for rare disease diagnosis and treatment.

SourcePacific Northwest Research Institute·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJan 12, 2026

Baveno VII guidelines: shaping the future of portal hypertension management

The Baveno VII consensus guidelines have reshaped portal hypertension management, focusing on early intervention and noninvasive diagnostics. Nonselective beta-blockers and transjugular intrahepatic portosystemic shunt (TIPS) are recommended for clinically significant portal hypertension diagnosis.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeSystematic review·DateDec 19, 2025

iPS cells from dish to freezer and back

Researchers at Kobe University developed a method to preserve iPS cells directly in their culture dishes using D-proline as a cryoprotectant. This allows for easy automation of the process, reducing costs and increasing efficiency in regenerative medicine and drug discovery research. The breakthrough enables the direct freezing, thawin...

SourceKobe University·JournalBiochemical Engineering Journal·TypeExperimental study·DateDec 18, 2025

Blood test may help identify which colon cancer patients benefit from NSAIDs

A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.

SourceAlliance for Clinical Trials in Oncology·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateDec 15, 2025

Identification of an immuno-inflammatory biomarker in the brain supports potentially more effective personalized treatment for major psychiatric disorders

A study published in Biological Psychiatry identifies a distinct immuno-inflammatory biomarker in the brain linked to immune system dysfunction and poorer response to standard treatments. The findings provide potential value for clinical prediction and precision therapies.

SourceElsevier·JournalBiological Psychiatry·TypeImaging analysis·DateDec 11, 2025

FAU engineers decode dementia type using AI and EEG brainwave analysis

Researchers at Florida Atlantic University have developed a deep learning model that detects and evaluates Alzheimer's disease (AD) and frontotemporal dementia (FTD) using EEG brainwave analysis. The model achieved over 90% accuracy in distinguishing individuals with dementia from cognitively normal participants.

SourceFlorida Atlantic University·JournalBiomedical Signal Processing and Control·TypeComputational simulation/modeling·DateDec 10, 2025

Study measures behavioral markers of alliance in support groups, viability of machine learning in mental health

Researchers measured dyadic alliance in support groups using computational algorithms and found verbal and nonverbal communication features, such as head poses and facial expressions, to be strong predictors of connection. The study suggests that AI can potentially identify behavioral markers of alliance and may have a role in mental h...

SourceUniversity of Kansas·TypeData/statistical analysis·DateDec 8, 2025

Journal of Nuclear Medicine Technology supplement highlights advances in theranostics and opportunities for growth

This supplement highlights key areas of focus for theranostics, including clinical lessons, education, science, multidisciplinary collaboration, and equity. It also explores new frontiers beyond oncology and examines finance, sustainability, policy, strategy, and future directions.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateDec 8, 2025

Next-generation targeted alpha therapy using astatine shows promise in thyroid cancer resistant to conventional treatment

A first-in-human study found that a single dose of the alpha-emitting radionuclide <sup> 211 </sup> At was both well-tolerated and effective in achieving disease control without molecularly targeted drugs. The therapy has potential to reduce treatment burden and broaden access to effective care for patients with refractory disease.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateDec 5, 2025

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: December 5, 2025

Recent studies explore new PET/CT imaging methods for prostate cancer staging and detection. Researchers assess improved performance of these advanced scans in detecting lymph node or bone spread, as well as their impact on treatment plans. Additionally, researchers examine the effectiveness of peptide receptor radionuclide therapy (PR...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateDec 5, 2025

From lab to clinic: CU Anschutz launches Phase 1 clinical trial of promising combination therapy for resistant ovarian cancer

Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.

SourceUniversity of Colorado Anschutz·JournalCancer Research Communications·DateDec 4, 2025

Engineering smarter care for ALS patients

University of Missouri researchers are combining in-home sensor technology with artificial intelligence to monitor daily changes in ALS patients' health. The system uses machine learning to estimate a patient's score on the ALS Functional Rating Scale Revised, predicting potential problems before they occur.

SourceUniversity of Missouri-Columbia·JournalFrontiers in Digital Health·DateDec 2, 2025

American College of Lifestyle Medicine publishes official position on lifestyle medicine as a framework for delivery of high-value, whole-person care

The American College of Lifestyle Medicine has published a position paper calling for the implementation of lifestyle medicine as a scalable and sustainable approach to address chronic disease burden and unsustainable healthcare costs. The framework includes training, board certification, clinical practice toolkits, and numerous resour...

SourceAmerican College of Lifestyle Medicine·JournalAmerican Journal of Lifestyle Medicine·TypeNews article·DateNov 25, 2025

Predicting how bones heal

An international team led by Lehigh University researcher Hannah Dailey is building predictive models to understand and eventually prevent bone healing complications. The team aims to incorporate biological differences into the model, using a library of imaging data from Switzerland's AO Research Institute Davos.

Texting helps UCSF reach more patients with needed care

A UCSF study found that a combination of outreach methods, including texts and live phone calls, significantly improves follow-up care for hard-to-reach patients. The integrated approach increased engagement among African American patients to 76.4% and improved overall reach rate by 3.5%, supporting their recovery and treatment outcomes.

SourceUniversity of California - San Francisco·JournalJournal of General Internal Medicine·DateNov 20, 2025

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: November 14, 2025

Researchers have made significant advancements in detecting and treating prostate cancer and ALS using innovative imaging techniques. A new PET tracer has been developed to track Huntington disease protein aggregates, offering a potential noninvasive monitoring tool. Additionally, studies have compared two types of PET scans for spotti...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateNov 14, 2025

Chinese Medical Journal study highlights exercise-induced vascular growth as anti-aging strategy

Exercise promotes angiogenesis and lymphangiogenesis through molecular signaling pathways, enhancing vascular function and immune response. This process offers potential interventions to combat age-related decline and disease, including cardiovascular diseases, muscle atrophy, and metabolic disorders.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateNov 10, 2025

HER2-targeted radioimmunotherapy regimen achieves complete and durable response in breast cancer model

A new radioimmunotherapy approach has been developed to treat HER2-positive breast cancer, resulting in complete and histologic cures with minimal toxicities. The treatment uses a pretargeted approach to directly target tumors, reducing the risk of radiation toxicity to healthy tissues.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateNov 7, 2025

New USC study identifies key genes linked to aggressive prostate cancer in people of African descent

A new USC study identified five genes linked to aggressive prostate cancer in people of African descent, including ATM, BRCA2, CHEK2, HOXB13 and PALB2. The researchers developed a method combining genetic risk scores with family history and specific variant presence for personalized monitoring and treatment strategies.

SourceKeck School of Medicine of USC·JournalEuropean Urology·TypeMeta-analysis·DateNov 5, 2025